• 2Q PBT rises 4.2% to RM20.2 million as compared to previous corresponding quarter
• Declares interim dividend of 0.5 sen per share
• Increased Federal Government budget allocation for healthcare sector and extension of public sector supply
agreements to boost future earnings

KUALA LUMPUR, 17 AUGUST 2021 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) posted a resilient second quarter financial performance with profit before tax rose 4.2% to RM20.2 million, supported by higher sales to the consumer healthcare and public health sector.

Revenue increased 8.4% to RM155.44 million in the quarter ended 30 June 2021 as compared to the preceding year corresponding quarter.

Net profit climbed 4.5% during the quarter to RM15.39 million. This resulted in a higher earnings per share of 2.18 sen, compared with 2.15 sen a year ago.

Cumulatively, net profit jumped 16.7% in the first six months this year to RM33.00 million, on the back of a 6.6% increase in revenue at RM321.89 million.

The Company has declared an interim dividend of 0.5 sen per share for the current quarter (2020: an interim dividend of 0.5 sen per share), equivalent to RM3.53 million (2020: 3.53 million). The Board of Directors has resolved that the Dividend Reinvestment Plan shall not apply to this dividend.

Duopharma Biotech Group Managing Director, Leonard Ariff Abdul Shatar, said stringent operational cost control measures will continue to help the Company navigate the challenging external environment during the pandemic.

“The pandemic has caused huge uncertainties in the business environment and resulted in disruptions in the global supply chain. In our industry, players are faced with issues such as purchasing certain raw and packaging materials. We seek to overcome these challenges by managing the risks the best we can,” Leonard Ariff said.

The Company is pleased to announce that the Drug Control Authority has on 16 July 2021 granted Duopharma (M) Sendirian Berhad (“DMSB”), a wholly-owned subsidiary of the Company, the conditional registration for emergency use for the COVILO Suspension for Injection COVID-19 Vaccine (Vero Cell), Inactivated (“Covid-19 Sinopharm Vaccine”) developed and produced by Beijing Institute of Biological Product Co. Ltd., a subsidiary of China National Biotec Group Company Limited.

The management of vaccine supply is expected to contribute positively to the future earnings of Duopharma Biotech Group for the financial year ending 31 December 2021.

“We are cautiously optimistic about our outlook. The government’s increased budget allocation for the healthcare sector, the extension of our public supply agreements, and the vaccine supply management will contribute positively to our future earnings,” Leonard Ariff said.